Diffuse Lung Disease

CHEST Regional Congress ATHENS 2019

June 27, 2019 Athens, Greece

Kevin K. Brown, MD Professor and Vice Chair Department of Medicine National Jewish Health Denver, Colorado Conflict of Interest Disclosure

Grant monies:


NIH-NHLBI


Foundations:

Pulmonary Fibrosis Foundation


Open Source Imaging Consortium (OSIC)

Consultancies: Astra Zeneca, Bayer, Biogen, Blade Boehringer-Ingelheim, Bristol Myers Squibb, Galecto, GeNO, Genoa, Lifemax, Lily, MedImmune, Pfizer, Pliant, Promedior, ProMetic, Genentech, and Veracyte. The problem





A



Courtesy of David A. Lynch, MD.

Penicillamine29Bone marrow transplantation Acquired immune deficiency syndromeAnticonvulsant30PostinfectionDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosis Giant cell arteritisAntibiotics32Respiratory bronchiolitisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edema Pulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumonia Bronchiolalveolar carcinomaMethotrexate39,40Pulmonary lymphoma AzathioprineAzathioprine41Chronic aspiration		Reference		Reference
Sciencerma 1-3 Dirary Supplement Polymyositis-Dermatomyositis 4,5 L-Tryptophan Systemic lupus erythematosus 6-8 Dopaminergic drugs Ankylosing spondylitis 12 Radiation Mixed connective tissue disease 13,14 Oxygen, Primary Sigren's syndrome 15,16 Paraquat Behcet's syndrome 17,18 Primary Sigren's syndrome Drug and treatment induced Sarcqidosis Sarcqidosis Antibiotics 20 Lymphangiolegrauloma Sulfasalazine 20 Lymphangiolegrauloma Cephalosporin 21 Tuberous sclerosis Amidatone 22 Lymphangiolic carcinomatosis Tocainide 23 Gaucher's disease Propranolol 24,25 Niermarky-Pudlak syndrome Gold 26–28 Adult respiratory distress syndrome Dilantin 30 Postifeccion Chemotherapeutic Agents 31 Wegener's granulomatosis Antibiotics 31 Wegener's granulomatosis Mittoroyulant Acquired immune deficiency syndrome Dilantin 30 Postifeccion Antindamatory Grant cell arretiris Giant cell arretiris Mittorycin C 32 <td>Collagen vascular disease associated</td> <td></td> <td>Drug and treatment induced - cont'd</td> <td></td>	Collagen vascular disease associated		Drug and treatment induced - cont'd	
Polymyositis-Dermatomyositis 4,5 t-Tryprophan Systemic lupus erythematosus 6–8 Dopaminergic drugs Rheumatoid arthritis 9–11 Bromocryptine Ankylosing spondylitis 12 Radiation Mixed connective tissue disease 13,14 Oxygen Primary Sjögren's syndrome 15,16 Paraquat Behcet's syndrome 17,18 Drug and treatment induced Sarcqidosis Sarcqidosis Antibiotics 20 Lymphangioleiomyomatosis Sulfasalazine 20 Lymphangioleiomyomatosis Antiartythmics 7 Tuberous carinomatosis Antiartythmics 7 Tuberous carinomatosis Antiartythmics 23 Gaucher's disease Propranolol 24,25 NitermansP-Juduk syndrome Gold 26–28 Adult respiratory disease Proinaliam 30 Postifiectron Antiartythmics 31 Wegener's granulomatosis Gold 26–8 Adult respiratory distress syndrome Penicillamine 29 Bone marrow transplantation Antitorytheres 31		1-3	Dietary Supplement	
Systemic lupus erythematosus6-8Dopaminergic drugsRheumatoid arthritis9-11BromocryptineAnkylosing spondylitis12RadiationMixed connective tissue disease13,14OxygenPrimary Sigren's syndrome15,16ParaquatBeheer's syndrome17,18Primary or unclassified disease relatedDrug and treatment inducedSarcqidosisAntibioticsEosinophilic granulomaNitrofurantoin19AmyloidosisSulfasalazine20LymphangitoloimyomatosisCephalosporin21Tuberous sclerosisAntibiotics22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Nitemann-Pick diseaseAntiinfammatoryHermansky-Pudlak syndromeGold26-28Aduler repiratory distress syndromeDilantin30PostinfectionDilantin31Wegener's granulomatosisAntibiotics33,34Interstriat acridiseaseMitiomycin C32Respiratory bronchiolitisBleomycin33,34Interstriat acridiseaseMulting Agents94,40Pulmonary veno-occlusive diseaseBusulfan35Alveolar proteinosisChorombucil37Diffuse alveolar proteinosisChorombucil37Diffuse alveolar carcinomaMittosourus42,43Eosinophilic preumoniaAntibiotics33,44Interstriat acridiseaseMitosourus36Alveolar proteinosis </td <td>Polymyositis-Dermatomyositis</td> <td>4.5</td> <td></td> <td>49</td>	Polymyositis-Dermatomyositis	4.5		49
Řheumatoid arthřitis 9–11 Ťromocryptine Ankylosing spondylitis 12 Radiation Mixed connective tissue disease 13, 14 Oxygen Primary Sjögren's syndrome 15, 16 Paraquit Beheet's syndrome 17, 18 Orug and treatment induced Sarcojdosis Antibiotics Eosinophilic granuloma Nitrofurantoin 19 Amyloidosis Sulfasalazine 20 Lymphangioleiomyomatosis Cephalosporin 21 Tuberous sclerosis Antiarrhythmics Neurofibromatosh Neurofibromatosh Antiarrhythmics 22 Lymphangioleiomyomatosis Tocainide 23 Gaucher's disease Propranolol 24,25 Nitemann-Pick disease Anticonvulsant 0 Zorinfection Antionguetic Agents 31 Wegener's granulomatosis Anticonvulsant 30 Posinfection Dilantin 30 Posinfection Altivaring Agents 33,34 Interstitial cardiogenic edema Mitomycin C 32 Respiratory disease Bleowycin 33,34 Interstitial cardiogenic edema Alkylating Agents Bloomatopia Bloopid paveubar hemorrhage Mitomycin C <td></td> <td></td> <td></td> <td></td>				
Ankylosing spondylitis12RadiationMixed connective tissue disease13,14Oxygen,Primary Sjögren's syndrome13,16ParaquarBeheet's syndrome17,18Primary or unclassified disease relatedDrug and treatment inducedSarcoidosisAntibiotics19AmyloidosisCephalosporin20LymphangiloicomyomatosisCephalosporin21Tuberous sclerosisAntibiotics22Lymphangiloi conyomatosisCalifasalazine20Lymphangilic carcinomatosisCalifasalazine21Tuberous sclerosisAntiadrone22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinfammatoryHermansky-Pudlak syndromeGold26-28Adult respiratory distress syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntibiotics32Respiratory bronchiolitisBleomycin33,44Interstitial cardiogenic edemaMitomycin C32Respiratory bronchiolitisBleomycin35Alveolar filling diseasesCyclophosphamide36Alveolar filling diseasesCyclophosphamide37Diffuse alveolar hemorrhageMethotrexare39,40Pulmonary lymphomaAtathoprine41Chronic aspirationAtathoprine41Chronic aspirationAtathoprine41Chronic aspiration <td>Rheumatoid arthritis</td> <td>9-11</td> <td></td> <td>50</td>	Rheumatoid arthritis	9-11		50
Mixed connective tissue disease13,14OxygenPrimary Sjögren's syndrome15,16ParaquatBehcet's syndrome17,18Primary or unclassified disease relatedOrug and treatment inducedSarcoidosisAntibioticsEosinophilic granulomaNitrofurantoin19AmyloidosisSulfasalazine20LymphangioleiomyomatosisCephalosporin21Tuberous sclerosisAntiarthythmics22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiarthythmics26–28Adult respiratory distress syndromeGold26–28Adult respiratory distress syndromeDilantin30PostinfectionDilantin31Wegener's granulomatosisAntibioticsGiant cell arteritisMitronycin C32Respiratory distress syndromeBleomycin33,34Interstitial cardiogenic edemaAlkylating Agents36Alveolar filling diseasesCyclophosphamide36Alveolar filling diseasesCyclophosphamide36Alveolar filling diseasesCyclophosphamide37Diffuse alveolar hemorrhageMethphalan38Lipoid pneumoniaAttibiorites37Diffuse alveolar hemorrhageMethphalan38Lipoid pneumoniaAttibiorites41Chronic aspirationAttibiorites37Diffuse alveolar hemorrhageMethphalan38Lipoid pneumonia<	Ankylosing spondylitis	12		51,52
Primary Sjögren's syndrome 15, 16 Paraquat Beheer's syndrome 17, 18 Primary or unclassified disease related Orug and treatment induced Sarcqidosis Antibiotics Eosinophilic granuloma Nitrofurantoin 19 Amyloidosis Sulfasalazine 20 Lymphangiolciomyomatosis Cephalosporin 21 Tuberous sclerosis Antibiotics Neurofibromatosis Antioarone Tocainide 23 Gaucher's disease Propranolol 24,25 Niemann-Pick disease Antiionamatory Hermansky-Pudlak syndrome Gold 26-28 Adult respiratory distress syndrome Dilantin 30 Postinfection Antibiotics Giant cell arteritis Mitomycin C 32 Respiratory bronchiolitis Buonycin 33,34 Interstitial cardiogenic edema Alkylating Agents Pulmonary toro-occlusive diseases Cyclophosphamide 36 Alveolar filing diseases Cyclophosphamide 37 Diffuse alveolar temorrhage Metphalan 38 Lipoid pneumonia Attimetabolites 39,40 Pulmonary truncoinisis Cyclophosphamide 41 Chronic aspiration Attinfamator		13.14	Oxygen.	53,54
Behcet's syndrome 17,18 Drug and treatment induced Sarcqidosis Antibiotics Eosinophilic granuloma Nitrofurantoin 19 Antiartytymics 20 Lymphangioleiomyomatosis 21 Tuberous sclerosis Antiartytymics Antiartytymics 22 Antiartytymics 23 Gaucher's disease 24,25 Propranolol 24,25 Mitrofurantoin 20 Penicillamine 29 Bone marrow transplantation Acquired immune deficiency syndrome Gold 26-28 Adult respiratory distress syndrome Dilantin 30 Dostinfection Chemotherapeutic Agents 31 Wegener's granulomatosis Antibiorics Giant cell arteritis Mitomycin C 32 Bleomycin 33,34 Interstitial cardiogenic edema Alkylating Agents Pulmonary tron-occlusive disease Guldandia 35 Alveolar proteinosis Chorombucil 37 Diffuse alveolar hemorrhage Mitoroyuch 36 Antibiorics Buomycin Alkylating Agents Buorochiolalveolar carcinoma	Primary Sjögren's syndrome			55,56
Primary or unclassified disease related Sarcoidosis Eosinophilic granulomaAntibioticsSarcoidosis Eosinophilic granulomaNitrofurantoin19AmyloidosisSulfasalazine20LymphangioleiomyomatosisCephalosporin21Tuberous sclerosisAntiarthythmicsNeurofibromatosisAmiodarone22Lymphangiric carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinfammatoryHermansky-Pudlak syndromeGold26–28Adult respiratory distress syndromeDilantin30PostinfectionDilantin30PostinfectionMiromycin C32Respiratory broncholitisBleomycin C32Respiratory broncholitisBleomycin C32Respiratory broncholitisBleomycin C32Respiratory broncholitisBleomycin C32Alveolar filling diseasesGulfan35Alveolar filling diseasesGyclophosphamide36Alveolar carcinomaMethotresate39,40Pulmonary veno-occlusive diseaseMuthotites41Chronic aspirationAntimetabolites42EosinophiliMethotresate39,40Pulmonary torolar carcinomaMethotresate44Alveolar microlithiasisAntimetabolites43Alveolar microlithiasisAntinfamine44Alveolar microlithiasisAntinetabolites44Alveolar microlithiasis				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AntibioticsEosinophilic granulomaNitrofurancoin19AmyloidosisSulfasalazine20LymphangioleiomyomatosisCephalosporin21Tuberous sclerosisAntiarthythmicsNeurofbromatosisAmiodarone22Lymphangiici carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinflammatoryHermansky-Pudlak syndromeGold26–28Adult respiratory distress syndromeGold26–28Adult respiratory distress syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegner's granulomatosisMitongycin C32Respiratory bronchiolitisBleomycin C32Respiratory bronchiolitisBleomycin C32Respiratory bronchiolitisBleomycin C32Alveolar filling diseasesGyclophosphamide36Alveolar filling diseasesGyclophosphamide36Alveolar filling diseasesGyclophosphamide41Chronic aspirationAntiborine41Chronic aspirationAntimetabolites44Alveolar microlinisisAtathoprine41Chronic aspirationAtathoprine41Chronic aspirationAntimetabolites44Alveolar microlinisisAntinetabolites44Alveolar microlinisisAttributing Agente46Metastatic pulmonary calcificationOther Cytooxic Crusps46Metastatic pulmonary calcification <td></td> <td>.,,</td> <td>Primary or unclassified disease related</td> <td></td>		.,,	Primary or unclassified disease related	
Nitrofurantoin19AmyloidosisSulfasalazine20LymphangioleiomyomatosisCephalosporin21Tuberous sclerosisAntiarthythmicsNeurofibromatosisAmiodarone22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiarthythmics24,25Niemann-Pick diseaseAntiodarone22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntinflammatoryHermansky-Pudlak syndromeGold26-28Adult respiratory distress syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstriai cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationAttimetabolites44Alveolar sarcoidosisMitrosoureas44Alveolar sarcoidosisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification				57
Sulfasalazine20LymphangjoleiomyomatosisCephalosporin21Tuberous sclerosisAntiarrhytmicsNeurofibromatosisAmidarone22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinflammatoryHermansky-Pudlak syndromeGold26-28Adult respiratory distress syndromePenicillamine29Bone marrow transplantationAntioorulsantAcquired immune deficiency syndromeDilantin30PostinfectionMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar proteinosisCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationAttinotices44Alveolar microlitiaisSulforambucil45Alveolar sarcoidosisMethotrexate44Alveolar microlitiaisSulforambucil45Alveolar sarcoidosisMitrosoureas44Alveolar sarcoidosisCorosine Arabinoside42,43Eosinophilic pneumoniaOther Cytotoxic Drugs46Metastatic pulmonary calcification			Eosinophilic granuloma	58
Cephalosporin21Tuberous sclerosisAntiarrhythmicsNeurofibromatoshsAmiodarone22Lymphangitic carcinomatoshsAmiodarone22Lymphangitic carcinomatoshsAntiarrhythmics23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinflammatoryHermansky-Pudlak syndromeGold26-28Adult respiratory distress syndromePenicillamine29Bone marrow transplantationAntiionulsantAcquired immune deficiency syndromeDilantin30PostinfectionDilantin31Wegener's granulomatosisAntibioticsGiant cell arteritisMitomycin C32Respiratory broncholitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar proteinosisCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar themorrhageMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationAttimetabolites44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisOther Cyotoxic Drugs46Metastatic pulmonary calcification				59
AntiarrhythmicsNeurofibromatosisAmiodarone22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinflammatoryHermansky-Pudlak syndromeGold26–28Adult respiratory distress syndromePenicillamine29Bone matrow transplantationAnticonvulsantAcquired immune deficiency syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseCyclophosphamide36Alveolar filling diseasesCyclophosphamide39,40Pulmonary lymphomaAntimetabolites41Chronic aspirationMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationMitrosoureas44Alveolar microlithiasisIstrosoureas44Alveolar seriodosisCarmustine (BCNU)46Metastatic pulmonary calcification			Lymphangioleiomyomatosis	60
Amiodarone22Lymphangitic carcinomatosisTocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinflammatoryHermansky-Pudlak syndromeGold26–28Adult respiratory distress syndromePenicillamine29Bone marrow transplantationAnticorvulsantAcquired immune deficiency syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntiboricsGiant cell arteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating Agents9Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMethotrezate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationAttrosoureas44Alveolar sarcoidosisMitrosoureas44Alveolar sarcoidosisLomustine (CCNU)45Alveolar sarcoidosis		21	Tuberous sclerosis	61
Tocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinflammatoryGold26-28.Penicillamine29Bone marrow transplantationAnticonvulsantDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaMikufan35Alveolar filling diseasesCyclophosphamide36Alveolar filling diseasesCyclophosphamide36Alveolar carcinomaMethotrezate39,40Pulmonary venomaMethotrezate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationMitrosoureas44Alveolar arccidosisCycosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar sarccidosisCarmustine (BCNU)46Metastatic pulmonary calcification	Antiarrhythmics		Neurofibromatosis	62
Tocainide23Gaucher's diseasePropranolol24,25Niemann-Pick diseaseAntiinflammatoryHermansky-Pudlak syndromeGold26-28Adult respiratory distress syndromePenicillamine29Bone marrow transplantationAntinonvulsantAcquired immune deficiency syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntibioticsGiant cell arteritisMitomycin C32Respiratory distesseBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan36Alveolar filling diseasesCyclophosphamide36Alveolar filling diseasesMethotrexate39,40Pulmonary lymphomaAntimetabolites39,40Pulmonary lymphomaMethotrexate39,40Pulmonary lymphomaMicrosoureas44Alveolar microlithissisCyclophosphamide42Chronic aspirationOrdiorambucil37Diffuse alveolar hemorrhageMethotrexate44Alveolar microlithissisCyctosine Arabinoside42,43Eosinophilic pneumoniaMicrosoureas44Alveolar microlithissisCurmustine (BCNU)46Metastatic pulmonary calcification	Amiodarone	22	Lymphangitic carcinomatosis	63
Antiinflammatory GoldHermansky-Pudlak syndromeGold26-28Adult respiratory distress syndromePenicillamine29Bone marrow transplantationAnticonvulsant30PostinfectionDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntibioticsGiant cell arteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstritial cardiogenic edemaAlkylating Agents9Julmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolites9,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)46Metastatic pulmonary calcification	Tocainide	23		64
Gold26-28Adult respiratory distress syndromePenicillamine29Bone marrow transplantationAnticonvulsant0PostinfectionDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntibioticsGiant cell arteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar sarcoidosisLomustine (BCNU)45Alveolar sarcoidosisOther Cytotoxic Drugs46Metastatic pulmonary calcification	Propranolol	24,25	Niemann-Pick disease	65
Gold26-28Adult respiratory distress syndromePenicillamine29Bone marrow transplantationAnticonvulsantAcquired immune deficiency syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntibioticsGiant cell arteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar sarcoidosisLomustine (BCNU)45Alveolar sarcoidosisOther Cytotoxic Drugs46Metastatic pulmonary calcification	Antiinflammatory		Hermansky-Pudlak syndrome	66
Penicillamine29Bone marrow transplantation Acquired immune deficiency syndromeAnticonvulsant30PostinfectionDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosis Giant cell arteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edema Pulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMethotrexate39,40Pulmonary lymphoma AzathioprineAzathioprine41Chronic aspirationKitosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcificationOther Cytotoxic Drugs44Metoart sarcoidosis	Gold	26-28		67,68
AnticonvulsantAcquired immune deficiency syndromeDilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntibioticsGiant cell arteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisOther Cytotoxic Drugs46Metastatic pulmonary calcification	Penicillamine	29		69,70
Dilantin30PostinfectionChemotherapeutic Agents31Wegener's granulomatosisAntibioticsGiant cell atteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolites39,40Pulmonary lymphomaAzathioprine41Chronic aspirationQytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar sarcoidosisLomustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification	Anticonvulsant			71
Chemotherapeutic Agents31Wegener's granulomatosis Giant cell arteritisAntibioticsGiant cell arteritisMitomycin C32Bleomycin33,34Alkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Cyclophosphamide36Chlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Cytosine Arabinoside42,43Nitrosoureas44Alveolar sarcoidosisLomustine (BCNU)45Alveolar sarcoidosisOther Cytotoxic Drugs	Dilantin	30		72,73
AntibioticsGiant cell arteritisMitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolites99,40Pulmonary lymphomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification	Chemotherapeutic Agents	31		74
Mitomycin C32Respiratory bronchiolitisBleomycin33,34Interstitial cardiogenic edemaAlkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolitesBronchiolalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification				75
Bleomycin33,34Interstitial cardiogenic edema Pulmonary veno-occlusive diseaseAlkylating Agents35Alveolar filling diseasesBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification	Mitomycin C	32		76
Alkylating AgentsPulmonary veno-occlusive diseaseBusulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification				
Busulfan35Alveolar filling diseasesCyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification		55,5 -		77
Cyclophosphamide36Alveolar proteinosisChlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification		35		
Chlorambucil37Diffuse alveolar hemorrhageMelphalan38Lipoid pneumoniaAntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification	Cyclophosphamide			
Melphalan38Lipoid pneumoniaAntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcification		37		78 79
AntimetabolitesBronchioloalveolar carcinomaMethotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcificationOther Cytotoxic Drugs46	Melphalan			80
Methotrexate39,40Pulmonary lymphomaAzathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumoniaNitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcificationOther Cytotoxic Drugs46				81
Azathioprine41Chronic aspirationCytosine Arabinoside42,43Eosinophilic pneumonia8Nitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcificationOther Cytotoxic Drugs46	Methotrexate	39,40		82
Cytosine Arabinoside42,43Eosinophilic pneumonia8Nitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcificationOther Cytotoxic Drugs46	Azathioprine			83
Nitrosoureas44Alveolar microlithiasisCarmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcificationOther Cytotoxic Drugs46Metastatic pulmonary calcification				84-86
Carmustine (BCNU)45Alveolar sarcoidosisLomustine (CCNU)46Metastatic pulmonary calcificationOther Cytotoxic Drugs46Metastatic pulmonary calcification				87
Lomustine (CCNU) 46 Metastatic pulmonary calcification Other Cytotoxic Drugs				57
Other Cytotoxic Drugs)/
		40	metastatic putnonary calcincation	
1/ Y/		47		
Nilutemide 48				

TABLE 1-1 Scope and Classification of Interstitial Lung Disease

	Reference		Reference	
Occupational and environmental exposure related	•	Occupational and environmental exposure related—cont'd	•	
Inorganic		Organic (hypersensitivity pneumonitis)-cont'd		
Silicosis	88-90	Maple bark stripper's lung		
Asbestosis	91,92	Malt worker's lung		
Talc pneumoconiosis	93,94	Tea grower's lung		
Kaolin pneumoconiosis	95	Suberosis (cork)		
Diatomaceous earth pneumoconiosis	96	Lycoperdonosis (lycoperdon puffballs)		
Aluminum oxide fibrosis	97	Compost lung		
Berylliosis	98,99	Humidifier lung		
Hard metal fibrosis	100	Sauna taker's lung		
Coal workers' pneumoconiosis	101			
Baritosis (barium)	102	Pauli's hypersensitivity pneumonitis		
Antimony pneumonoconiosis	103			
Silicosiderosis (iron oxide)	103	Pituitary snuff taker's disease		
	104	Detergent worker's lung (isocyanates)		
Polyvinyl chloride pneumoconiosis	105			
Shale pneumoconiosis	108	Japanese summer-type hypersensitivity		
Siderosis (arc welder's lung)	107	Thatched roof lung		
Stannosis (tin)		Familial hypersensitivity pneumonitis		
Silicone pneumonitis	109	(wood dust)		
Organic (hypersensitivity pneumonitis)	110-131	Vineyard sprayer's lung		
Bagassosis (sugar cane)		Laboratory worker's lung (rat urine)		
Bird breeder's lung (pigeons,		Mollusk shell hypersensitivity pneumonitis		
parakeets, and so on)		Fibrotic disorders of unknown etiology		
Chicken handler's lung			122	
Duck fever	Acute interstitial pneumonia		132	
Dove handler's disease	Idiopathic pulmonary fibrosis		133	
Farmer's lung	Familial idiopathic pulmonary fibrosis		134	
Coffee worker's lung	Lymphocytic interstitial pneumonia		135	
Tobacco grower's lung		Bronchiolitis obliterans organizing pneumonia	136,137	
Coptic disease (mummy wrappings)		(cryptogenic organizing pneumonia)	120	
Cheese worker's lung		Autoimmune hemolytic anemia	138	
Fishmeal worker's lung		'Idiopathic thrombocytopenic purpura	139	
Furrier's lung		Cryoglobulinemia	140	
Meat worker's lung		Inflammatory bowel disease	141	
Mushroom worker's lung		Coeliac disease	142	
Paprika splitter's lung		Whipple's disease	143	
Miller's lung (wheat flour)	Primary biliary cirrhosis 144			
Wood worker's disease		Chronic active hepatitis	145	
Sequoiosis		Cryptogenic cirrhosis	145	

TABLE 1-1 Scope and Classification of Interstitial Lung Disease-cont'd

The interstitial lung diseases include a wide variety of pulmonary disorders that diffusely affect all anatomic compartments of the lung. The interstitial lung diseases include a wide variety of pulmonary disorders that diffusely affect all anatomic compartments of the lung.

The final diagnosis often requires information from a number specialities

Clinical context

Chest imaging pattern


Pathologic pattern


Clinical context


Chest imaging pattern

Pathologic pattern

Diagnosis










The clinical context improves the diagnostic accuracy of radiologists


Degree of Difficulty Based on the Diagnosis	No Cue	Irrelevant Cue	Directive (Correct) Cue
Normal (obvious)	0.81	0.78	0.81
Normal (difficult)	0.73	0.73	0.73
Abnormal (difficult)	0.44	0.48	0.67
Abnormal (obvious)	0.92	0.82	0.89


Potchen, J Am Coll Radiol 2006; 3:423-432



















The problem areas



Confident Diagnosis

Working Diagnosis



Useful clinical questions

Review

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper

David A Lynch, Nicola Sverzellati, William D Travis, Kevin K Brown, Thomas V Colby, Jeffrey R Galvin, Jonathan G Goldin, David M Hansell, Yoshikazu Inoue, Takeshi Johkoh, Andrew G Nicholson, Shandra L Knight, Suhail Raoof, Luca Richeldi, Christopher J Ryerson, Jay H Ryu, Athol U Wells

Panel 2: Clinical checklist for alternative diagnoses

General

What are the severity, duration, and pace of the primary respiratory symptoms?

Systemic autoimmune disease

- Are symptoms or signs of a systemic autoimmune disorder present?
- Are serological findings suggestive of an autoimmune disorder? Eg, rheumatoid arthritis, systemic sclerosis, polymyositis and dermatomyositis, Steven-Johnson syndrome, or mixed-connective tissue disease.

Other systemic disease (sarcoid, immune-system abnormalities)

Is there evidence of other organ involvement?

Hypersensitivity pneumonitis

- Does the patient have a clinically relevant exposure to an antigen, generally inhaled, known to result in the development of hypersensitivity pneumonitis?
- Do they have pets, including birds?
- What are they exposed to in their home or work environment? Is there water damage?
- Is the exposure clinically significant?
- Is the intensity clinically significant?
- Is there a temporal association between the exposure and symptom onset?

Occupational and environmental lung disease

- Does the patient work in an occupation known to be at risk for the development of lung disease?
- What do they do in their current job and previous jobs?
- What avocational exposures exist?

Drug-induced lung disease

 Does the patient use any medicines, herbs, vitamins, supplements, or recreational drugs that could account for the presence of lung disease?

Specific genetic syndromes

- Is there a family history of lung fibrosis?
- Is there evidence of premature graying, cryptogenic cirrhosis, aplastic anaemia, myelodysplasia, macrocytosis, or thrombocytopenia?

Systemic autoimmune disease

- Are symptoms or signs of a systemic autoimmune disorder present?
- Are there serological findings suggestive of an autoimmune disorder? e.g., rheumatoid arthritis, systemic sclerosis, polymyositis and dermatomyositis, Sjogren's or mixed-connective tissue disease.

Other systemic disease (e.g., sarcoid, immunesystem abnormalities)

• Is there evidence of other organ involvement?

Hypersensitivity pneumonitis

- Does the patient have a clinically relevant exposure to an antigen, generally inhaled, known to result in the development of hypersensitivity pneumonitis?
- Do they have pets, including birds?
- What are they exposed to in their home or work environment? Is there water damage?
- Is the exposure clinically significant?
- Is the intensity clinically significant?
- Is there a temporal association between the exposure and symptom onset?


Occupational and environmental lung disease

- Does the patient work in an occupation known to be at risk for the development of lung disease?
- What do they do in their current job and previous jobs?
- What avocational exposures exist?
- Drug-induced lung disease
 - Does the patient use any medicines, herbs, vitamins, supplements, or recreational drugs that could account for the presence of lung disease?

Specific genetic syndromes

- Is there a family history of lung fibrosis?
- Is there evidence of premature graying, cryptogenic cirrhosis, aplastic anaemia, myelodysplasia, macrocytosis, or thrombocytopenia in the patient or the extended family?

Interstitial Lung Disease



Idiopathic Interstitial Pneumonias

Idiopathic Pulmonary Fibrosis (IPF)


Nonspecific Interstitial Pneumonia (NSIP)

Cryptogenic Organizing Pneumonia (COP)

Desquamative Interstitial Pneumonia/ Respiratory Bronchiolitis-ILD (DIP/RBILD)

Acute Interstitial Pneumonia (AIP)

Interstitial Lung Disease




Infections

Atypical Pneumonia

Mycoplasma Chlamydia Viral Pneumocystis Mycobacterial

Interstitial Lung Disease



Genetic conditions

Hermansky Pudlak

Familial Interstitial Pneumonia

Defects in which of the following pathways have been associated with pulmonary fibrosis?

- 1. Airway mucins
- 2. Telomere length
- 3. Toll-like receptors
- 4. Desmoplakin
- 5. All of the above


Defects in which of the following pathways have been associated with pulmonary fibrosis?

- 1. Airway mucins
- 2. Telomere length
- 3. Toll-like receptors
- 4. Desmoplakin
- 5. All of the above

Summary of common genetic variants linked to idiopathic pulmonary fibrosis (IPF)


Locus	Gene	SNP	IPF risk	IPF survival
2q14	IL1RN	rs408392	Yes	
2010. - 10.200		rs419598	Yes	
		rs2637988	Yes	
3q26	hTR	rs6793295	Yes	
4q13	IL8	rs4073	Yes	
		rs2227307	Yes	
4q22	FAM13A	rs2609255	Yes	
4q35	TLR3	rs3775291		Harmful
5p15	TERT	rs2736100	Yes	
6p21	CDKN1A	rs2395655	Yes	Harmful
6p21	HLA-DRB1		Yes	
6q24	DSP	rs2076295	Yes	
7q22	Intergenic	rs47274443	Yes	
10024	UBFC1	rs11191865	Yes	
11p15	MUC5B	rs35705950	Yes	Protective
	MUC2	rs7934606	Yes	
	TOLLIP	rs111521887	Yes	
	TOLLIP	rc57/389/	Yes	
	TOLLIP	rs2743890	Yes	Protective
13q34	AIPTIA	rs1278769	res	
14q21	MDGA2	rs7144383	Yes	
15q14-15	Intergenic	rs2034650	Yes	
17q13	TP53	rs12951053	No	Harmful
	TP53	rs12602273	No	Harmful
17q21	MAPT	rs1981997	Yes	
17q21	SPPL2C	rs17690703	Yes	
19q13	DPP9	rs12610495	Yes	
19q13	TGFB1	rs1800470	No	Harmful

Kropski JA et al, Eur Respir J 2015




Rare genetic variants linked to familial interstitial pneumonia (FIP)

Kropski JA et al, Eur Respir J 2015



Savage and Bertuch, Genet Med 2010 December; 12(12)

Interstitial Lung Disease



Systemic Disorders

Sarcoidosis

Connective Tissue Disease Immunodeficiency Malignancy

Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA

Alison M. Gizinski • Margherita Mascolo • Jennifer L. Loucks • Alma Kervitsky • Richard T. Meehan • Kevin K. Brown • V. Michael Holers • Kevin D. Deane

Gizinski, Clin Rheumatol 2009

Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease

Aryeh Fischer^{*}, Joshua J. Solomon, Roland M. du Bois, Kevin D. Deane, Amy L. Olson, Evans R. Fernandez-Perez, Tristan J. Huie, Allen D. Stevens, Mary B. Gill, Avi M. Rabinovitch, David A. Lynch, David A. Burns, Isabel S. Pineiro, Steve D. Groshong, Rosane D. Duarte Achcar, Kevin K. Brown, Richard J. Martin, Jeffrey J. Swigris

Fischer et al, Respiratory Medicine 2012

It is common for patients with ILD to have signs/symptoms/serologic abnormalities suggestive, but not diagnostic of an autoimmune disease. What impact does this have on prognosis?

- 1. Better response to immunosuppression
- 2. Shorter survival
- 3. Longer survival
- 4. Higher risk of treatment complications
- 5. Unknown

It is common for patients with ILD to have signs/symptoms/serologic abnormalities suggestive, but not diagnostic of an autoimmune disease. What impact does this have on prognosis?

- 1. Better response to immunosuppression
- 2. Shorter survival
- 3. Longer survival
- 4. Higher risk of treatment complications

5. Unknown


ERS/ATS TASK FORCE INTERSTITIAL LUNG DISEASE

An official European Respiratory Society/ American Thoracic Society research statement: interstitial pneumonia with autoimmune features

Aryeh Fischer^{1,17,18}, Katerina M. Antoniou², Kevin K. Brown³, Jacques Cadranel⁴, Tamera J. Corte^{5,18}, Roland M. du Bois⁶, Joyce S. Lee^{7,18}, Kevin O. Leslie⁸, David A. Lynch⁹, Eric L. Matteson¹⁰, Marta Mosca¹¹, Imre Noth¹², Luca Richeldi¹³, Mary E. Strek^{12,18}, Jeffrey J. Swigris^{3,18}, Athol U. Wells¹⁴, Sterling G. West¹⁵, Harold R. Collard^{7,18,19} and Vincent Cottin^{16,18,19}, on behalf of the "ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD"



Interstitial Lung Disease





Medications/Drugs/Tobacco Occupational Avocational Environmental Accidental

ORIGINAL ARTICLE

Interstitial Lung Disease in India Results of a Prospective Registry

Abstract

Rationale: Interstitial lung disease (ILD) is a heterogeneous group of acute and chronic inflammatory and fibrotic lung diseases. Existing ILD registries have had variable findings. Little is known about the clinical profile of ILDs in India.

Objectives: To characterize new-onset ILDs in India by creating a prospective ILD using multidisciplinary discussion (MDD) to validate diagnoses.

Methods: Adult patients of Indian origin living in India with new-onset ILD (27 centers, 19 Indian cities, March 2012–June 2015) without malignancy or infection were included. All had connective tissue disease (CTD) serologies, spirometry, and high-resolution computed tomography chest. ILD pattern was defined by high-resolution computed tomography images. Three groups independently made diagnoses after review of clinical data including that from prompted case report forms: local site investigators, ILD experts at the National Data Coordinating Center (NDCC; Jaipur, India) with MDD, and experienced ILD experts at the Center for ILD (CILD; Seattle, WA) with MDD. Cohen's κ was used to assess reliability of interobserver agreement.

Measurements and Main Results: A total of 1,084 patients were recruited. Final diagnosis: hypersensitivity pneumonitis in 47.3% (n = 513; exposure, 48.1% air coolers), CTD-ILD in 13.9%, and idiopathic pulmonary fibrosis in 13.7%. Cohen's κ : 0.351 site investigator/CILD, 0.519 site investigator/NDCC, and 0.618 NDCC/CILD.

Conclusions: Hypersensitivity pneumonitis was the most common new-onset ILD in India, followed by CTD-ILD and idiopathic pulmonary fibrosis; diagnoses varied between site investigators and CILD experts, emphasizing the value of MDD in ILD diagnosis. Prompted case report forms including environmental exposures in prospective registries will likely provide further insight into the etiology and management of ILD worldwide.

Keywords: interstitial lung disease; registry; India

Singh et al, Am J Respir Crit Care Med 2017; 195(6), 801-813


Which pathologic pattern is seen in patients with hypersensitivity pneumonitis?


- Non-specific interstitial pneumonia (NSIP)
- 2. Usual interstitial pneumonia (UIP)
- 3. Airway-centered granulomatous pneumonitis
- 4. Organizing pneumonia
- 5. All of the above

Which pathologic pattern is seen in patients with hypersensitivity pneumonitis?

- Non-specific interstitial pneumonia (NSIP)
- 2. Usual interstitial pneumonia (UIP)
- 3. Airway-centered granulomatous pneumonitis
- 4. Organizing pneumonia
- 5. All of the above


Interstitial Lung Disease





Confident Diagnosis


Working Diagnosis



Confident Diagnosis


Working Diagnosis

ASCEND/Pirfenidone Screen failures



King et al, New Engl J Med 2014

ASCEND/Pirfenidone Screen failures



King et al, New Engl J Med 2014

Comparison of Selected Inclusion/Exclusion Criteria

Inclusion/Exclusion criteria	Pirfenidone	Nintedanib	PANTHER/NAC
Screen failure rate	64%	29%	33%
Diagnostic criteria	ATS/ERS	"Modified" ATS/ERS	"Modified" ATS/ERS
HRCT and Surgical Lung Biopsy review	Central	Central	Local + Central
Age	40-80 years	> 40 years	35 - 85 years
Duration of disease	6 – 48 months	< 5 years	< 4 years
FVC	50% - 90%	> 50%	> 50%
FEV1/FVC	> 79%	> 69%	> 64%
DLCO	30% - 90%	30% - 79%	> 30%
PaO2	None	None	> 54
6 MWT	> 150 m	None	None

Comparison of Selected Inclusion/Exclusion Criteria

Inclusion/Exclusion criteria	Pirfenidone	Nintedanib	PANTHER/NAC
Screen failure rate	64%	29%	33%
Diagnostic criteria	ATS/ERS	"Modified" ATS/ERS	"Modified" ATS/ERS
HRCT and Surgical Lung Biopsy review	Central	Central	Local + Central
Age	40-80 years	> 40 years	35 - 85 years
Duration of disease	6 – 48 months	< 5 years	< 4 years
FVC	50% - 90%	> 50%	> 50%
FEV1/FVC	> 79%	> 69%	> 64%
DLCO	30% - 90%	30% - 79%	> 30%
PaO2	None	None	> 54
6 MWT	> 150 m	None	None

Measuring Agreement Among Observers

Kappa = <u>Actual Agreement Beyond Chance</u> Potential Agreement Beyond Chance

Kappa Value	Strength of Agreement	
< 0	Poor	
0–0.2	Slight	
0.2–0.4	Fair	
0.4–0.6	Moderate	
0.6–0.8	Substantial	
0.8–1.0	Almost perfect	

Clinically useful agreement

Sackett DL, et al. *Clinical Epidemiology: A basic science for clinical medicine*; 1991:29. Landis JR, Koch GG. *Biometrics.* 1977;33:159-174.

The Problem with Pathology

The Problem with Pathology

Diagnosis	Lobar diagnosis (n = 98)	Final diagnosis (n = 48)
UIP	0.40 Moderate	0.49 Moderate
NSIP	0.32 Fair	0.32 Fair
ОР	0.59	0.67
HP	0.39	0.35
Sarcoidosis	0.76	0.82
Normal	0.07	N/A
Overall	0.39 Fair	0.43 Moderate

Kappa coefficients (k) between lobar and final diagnoses in 48 patients

Nicholson AG et al, Thorax 2004

Pulmonary embolus Kappa = 0.72-0.96 Cystic lung disease Kappa = .77-1.0

	Median (range) kw coefficient of agreement
IPF	0.63 (0.48–0.78)
NSIP	0.51 (0.27–0.78)
Sarcoidosis	0.70 (0.58–0.84)
Extrinsic allergic alveolitis	0.60 (0.36–0.78)
Cryptogenic Organizing Pneumonia	0.49 (0.06–0.76)
Smoking related ILD	0.51 (0.20–0.73)

Aziz ZA et al, Thorax 2004

The Presence of Honeycombing on HRCT

Interpretation of	Interpretation of (
Study-Site Radiologist	Present	Absent	Total
Present	251 (79.9%)	12 (3.8%)	263
Absent	36 (11.5%)	15 (4.8%)	51
Total	287	27	314

Agreement among experts and study site $\kappa = 0.31 (0.16-0.45)$

Lynch et al, Am J Respir Crit Care Med 2005

The Presence of Honeycombing on HRCT

Interpretation of	Interpretation of (
Study-Site Radiologist	Present	Absent	Total
Present	251 (79.9%)	12 (3.8%)	263
Absent	36 (11.5%)	15 (4.8%)	51
Total	287	27	314

Agreement among experts and study site $\kappa = 0.31 (0.16-0.45)$

Agreement among expert readers

 $\kappa = 0.21 \ (0.09 - 0.32)$

Lynch et al, Am J Respir Crit Care Med 2005

Agreement on the Presence of a UIP Pattern

	Diagnosis of the First Two Readers*	Consensus Diagnosis Based on Up to Three Reviews
Consistent with IPF	256 (81.3%)	283 (89.8%)
Inconsistent with IPF	15 (4.8%)	30 (9.5%)
Lack of agreement	44 (14.0%)	2 (0.6%)

Agreement among expert readers $\kappa = 0.33 (0.18-0.48)$

Lynch et al, Am J Respir Crit Care Med 2005

Agreement among readers for CT findings

Radiology Feature	к Coefficient (95% CI)	P Value
UIPa	0.31 (0.21-0.42)	<.0001
Honeycombing ^a	0.49 (0.38-0.60)	<.0001
Ground-glass ^a	0.39 (0.27-0.52)	<.0001
Zonal distribution ^b	0.24 (0.14-0.35)	<.0001
Axial distribution ^b	0.25 (0.15-0.35)	<.0001

Chung et al. Chest 2015

Eur Respir J 2008; 31: 585–591 DOI: 10.1183/09031936.00063706 Copyright@ERS Journals Ltd 2008

Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis

M. Thomeer^{*,#}, M. Demedts^{*}, J. Behr[¶], R. Buhl⁺, U. Costabel[§], C.D.R. Flower^f, J. Verschakelen^{*}, F. Laurent^{**}, A.G. Nicholson^{##}, E.K. Verbeken^{*}, F. Capron^{¶¶}, M. Sardina⁺⁺, G. Corvasce⁺⁺ and I. Lankhorst⁺⁺, and the Idiopathic Pulmonary Fibrosis International Group Exploring *N*-Acetylcysteine I Annual (IFIGENIA) study group




Thomeer M et al, Eur Respir J 2008

Weighted Kappa Among HRCT Reviewers


First author [Ref.]	Year	Interobserver agreement κ coefficient	Study population	Subjects n
GRENIER [10]	1991	0.64-0.78	Sarcoidosis	53
			Pulmonary fibrosis	33
			Histiocytosis X	17
			Other ILD	37
WELLS [19]	1993	0.58-0.76	Systemic sclerosis	35
			IPF	21
COLLINS [8]	1994	0.48	Systemic sclerosis	63
			IPF	63
KAZEROONI [20]	1997	0.51-0.83	UIP; DIP	24; 1
MACDONALD [9]	2001	0.40	NSIP	21
			UIP	32
HUNNINGHAKE [7]	2001	0.54	IPF	54
			Non-IPF	37
FLAHERTY [3]	2003	0.43	NSIP	23
			UIP	73
Azız [21]	2004	0.50	DPLD	131
Present study		0.40	UIP	156
			Non-UIP	23

Thomeer M et al, Eur Respir J 2008



Confident Diagnosis

Working Diagnosis



Clinician ĸ	Radiologist κ

	Clinician ĸ	Radiologist κ
HRCT alone	0.42	0.72

	Clinician κ	Radiologist κ
HRCT alone	0.42	0.72
History + Clinical	0.49	0.80

	Clinician κ	Radiologist κ
HRCT alone	0.42	0.72
History + Clinical	0.49	0.80
Clinician/Radiologist Discussion	0.67	0.78

	Clinician κ	Radiologist κ
HRCT alone	0.42	0.72
History + Clinical	0.49	0.80
Clinician/Radiologist Discussion	0.67	0.78
Clinician/ Radiologist/ Pathologist Discussion	0.71	0.81

	Clinician κ	Radiologist κ
HRCT alone	0.42	0.72
History + Clinical	0.49	0.80
Clinician/Radiologist Discussion	0.67	0.78
Clinician/ Radiologist/ Pathologist Discussion	0.71	0.81
Consensus	0.84	0.84

Summary

- ILD consists of a variety of disorders with divergent outcomes
- The clinical context separates idiopathic from non-idiopathic disease and provides the background for interpretation of both the chest images and lung pathology
- The combination of <u>the appropriate clinical</u> <u>context</u> and <u>a confident HRCT pattern diagnosis</u> may be diagnostic
- A multidisciplinary discussion of the relevant data increases diagnostic confidence